{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:39:12Z","timestamp":1770223152276,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T00:00:00Z","timestamp":1490140800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00467-017-3579-6","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T16:02:35Z","timestamp":1490198555000},"page":"1221-1232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease"],"prefix":"10.1007","volume":"32","author":[{"given":"Nicholas J. A.","family":"Webb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley A.","family":"Warady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine M.","family":"Dell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry A.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Linde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Eldred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Dufek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"3579_CR1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2013) Mineral & bone disorder in chronic kidney disease http:\/\/www.niddk.nih.gov\/health-information\/health-topics\/kidney-disease\/chronic-kidney-disease-mineral-and-bone-disorder\/Pages\/facts.aspx . Accessed 26 Jan 2016"},{"key":"3579_CR2","unstructured":"National Kidney Foundation (2003) K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[4 Suppl 3]:S1\u2013S201"},{"key":"3579_CR3","unstructured":"National Kidney Foundation (2005) K\/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46[4 Suppl 1]:S1\u2013S103"},{"issue":"1","key":"3579_CR4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71(1):31\u201338","journal-title":"Kidney Int"},{"issue":"5","key":"3579_CR5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem-67-5-876","volume":"67","author":"TO Pitts","year":"1988","unstructured":"Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB (1988) Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67(5):876\u2013881","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3579_CR6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000441095","volume":"42","author":"M Cozzolino","year":"2015","unstructured":"Cozzolino M, Covic A, Martinez-Placencia B, Xynos K (2015) Treatment failure of active vitamin D therapy in chronic kidney disease: predictive factors. Am J Nephrol 42(3):228\u2013236","journal-title":"Am J Nephrol"},{"key":"3579_CR7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0272-6386(12)80977-2","volume":"23","author":"E Slatopolsky","year":"1994","unstructured":"Slatopolsky E, Delmez JA (1994) Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23:229\u2013236","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3579_CR8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00467-015-3190-7","volume":"31","author":"J Kumar","year":"2016","unstructured":"Kumar J, McDermott K, Abraham AG, Friedman LA, Johnson VL, Kaskel FJ, Furth SL, Warady BA, Portale AA, Melamed ML (2016) Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort. Pediatr Nephrol 31(1):121\u2013129","journal-title":"Pediatr Nephrol"},{"key":"3579_CR9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","volume":"38","author":"J Blacher","year":"2001","unstructured":"Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938\u2013942","journal-title":"Hypertension"},{"issue":"2","key":"3579_CR10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000325454","volume":"32","author":"D Brancaccio","year":"2011","unstructured":"Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G, Caruso MR, Cascone C, Costanzo AM, di Luzio Paparatti U, Mazzaferro S, FARO Study Group (2011) Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood Purif 32(2):124\u2013132","journal-title":"Blood Purif"},{"key":"3579_CR11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478\u20131483","journal-title":"N Engl J Med"},{"issue":"7","key":"3579_CR12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/15.7.1014","volume":"15","author":"AP Guerin","year":"2000","unstructured":"Guerin AP, London GM, Marchais SJ, Metivier F (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15(7):1014\u20131021","journal-title":"Nephrol Dial Transplant"},{"key":"3579_CR13","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1\u2013S130","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"3579_CR14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00467-007-0671-3","volume":"23","author":"K Wesseling","year":"2008","unstructured":"Wesseling K, Bakkaloglu S, Salusky I (2008) Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 23(2):195\u2013207","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"3579_CR15","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69(11):1945\u20131953","journal-title":"Kidney Int"},{"issue":"12","key":"3579_CR16","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1681\/ASN.V3121938","volume":"3","author":"R Mathias","year":"1993","unstructured":"Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W (1993) Renal bone disease in pediatric and young adult patients on hemodialysis in a children\u2019s hospital. J Am Soc Nephrol 3(12):1938\u20131946","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3579_CR17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1053\/j.ajkd.2007.03.008","volume":"49","author":"LA Greenbaum","year":"2007","unstructured":"Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB (2007) Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 49(6):814\u2013823","journal-title":"Am J Kidney Dis"},{"key":"3579_CR18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800\u2013807","journal-title":"J Am Soc Nephrol"},{"issue":"5 suppl 5","key":"3579_CR19","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38[5 suppl 5]:S45\u2013S50","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"3579_CR20","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00467-006-0204-5","volume":"21","author":"W Seeherunvong","year":"2006","unstructured":"Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G (2006) Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 21(10):1434\u20131439","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"3579_CR21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"3579_CR22","unstructured":"AbbVie Inc. (2015) Zemplar\u00ae (paricalcitol capsules). Full prescribing information. AbbVie Inc., North Chicago"},{"issue":"4","key":"3579_CR23","first-page":"315","volume":"56","author":"J Lindberg","year":"2001","unstructured":"Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56(4):315\u2013323","journal-title":"Clin Nephrol"},{"issue":"1","key":"3579_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/ki.1987.176","volume":"32","author":"IB Salusky","year":"1987","unstructured":"Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatopolsky E, Coburn JW (1987) \"High-dose\" calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32(1):89\u201395","journal-title":"Kidney Int"},{"issue":"1","key":"3579_CR25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","volume":"79","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Juppner H, Salusky IB (2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79(1):112\u2013119","journal-title":"Kidney Int"},{"issue":"1","key":"3579_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1523-1755.1998.00724.x","volume":"53","author":"BD Kuizon","year":"1998","unstructured":"Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53(1):205\u2013211","journal-title":"Kidney Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-017-3579-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T19:55:31Z","timestamp":1658865331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-017-3579-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3579"],"URL":"https:\/\/doi.org\/10.1007\/s00467-017-3579-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}